HK Stock Market Move | EXTREME VISION (06636) once rose more than 12%, the stock price hit a new high since listing, with a cumulative increase of over 1.8 times compared to the IPO price.
Extreme Vision (06636) surged more than 12% at one point, reaching a high of 113.8 Hong Kong dollars, a new record high since its listing, representing a 1.8-fold increase from the IPO price of 40 Hong Kong dollars.
EXTREME VISION (06636) once surged over 12%, reaching a high of 113.8 Hong Kong dollars, setting a new record high for the company's stock since its IPO at 40 Hong Kong dollars, representing a 1.8-fold increase. As of the time of writing, it rose by 6.34% to 107.4 Hong Kong dollars, with a trading volume of 207 million Hong Kong dollars.
Public information shows that EXTREME VISION is a provider of AI-based computer vision solutions, offering end-to-end enterprise solutions covering development, deployment, and management for businesses in various industries. According to Frost & Sullivan, the company ranks eighth in the emerging computer vision solutions market in China based on revenue projections for 2024.
Financial data shows that from 2022 to 2024, the company achieved revenues of 102 million yuan, 128 million yuan, and 257 million yuan, respectively. In the first three quarters of 2025, revenues further increased to 136 million yuan, with revenue growth mainly attributed to the continuous expansion of the company's algorithm marketplace, the continuous expansion of industry coverage, and the gradual implementation of large-scale model solutions.
Related Articles

RELIANCE GLO HL (00723) is expected to achieve other income from listed securities investments of approximately HK$61.6 million in the fiscal year 2026, representing a year-on-year increase of approximately 16.74 times.

CITIC SEC (06030) released its first quarter performance report with a net profit attributable to shareholders of 10.216 billion yuan, an increase of 54.6% year-on-year.

SBP GROUP (01177): Naltrexone sustained-release tablets "peripheral -opioid receptor antagonist" approved for listing in the Greater Bay Area
RELIANCE GLO HL (00723) is expected to achieve other income from listed securities investments of approximately HK$61.6 million in the fiscal year 2026, representing a year-on-year increase of approximately 16.74 times.

CITIC SEC (06030) released its first quarter performance report with a net profit attributable to shareholders of 10.216 billion yuan, an increase of 54.6% year-on-year.

SBP GROUP (01177): Naltrexone sustained-release tablets "peripheral -opioid receptor antagonist" approved for listing in the Greater Bay Area






